Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits

Current Topics in Behavioral Neurosciences

Volumn 22, Issue , 2014, Pages 303-330

  Hatami, Asa ^a   Chesselet, Marie Francoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavior; Dementia; Mouse; Parkinson s disease; Rat

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; DOPAMINE TRANSPORTER; TRANSCRIPTION FACTOR PITX3; VIRUS VECTOR;

ALZHEIMER DISEASE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; GENE EXPRESSION; GENE MUTATION; HUMAN; LEWY BODY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE; RAT; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; COGNITION DISORDERS; DEMENTIA; DISEASE MODELS, ANIMAL; MICE; PARKINSON DISEASE; RATS;

EID: 84941123145     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2014_355     Document Type: Article

References (99)

1. Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with parkinson's disease. Brain Pathol 20:633-639
2. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho W-H, Castillo PE, Shinsky N, Verdugo JMG, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252
3. Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Romer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B (2013) Time course and progression of wild type alpha-Synuclein accumulation in a transgenic mouse model. BMC Neuroscience 14:6
4. Beach T, Adler C, Lue L, Sue L, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White C III, Akiyama H, Caviness J, Shill H, Connor D, Sabbagh M, Walker D (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613-634
5. Botton PH, Costa MS, Ardais AP, Mioranzza S, Souza DO, da Rocha JBT, Porciúncula LO (2010) Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav Brain Res 214:254-259
6. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249:1-5
7. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
8. Braak H, Rüb U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248:255-258
9. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP, N. S. G. (2010) Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 133:2382-2393
10. Chen PE, Specht CG, Morris RGM, Schoepfer R (2002) Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus. Eur J Neurosci 16:154-158
11. Chesselet M-F, Richter F (2011) Modelling of Parkinson's disease in mice. Lancet Neurol 10:1108-1118
12. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM (2010) Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline. J Neurosci 30:7281-7289
13. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8:1150-1157
14. Farrer M, Kachergus J, Forno L, Lincoln S, Wang D-S, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW (2004) Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol 55:174-179
15. Fernagut PO, Tison F (2012) Animal models of multiple system atrophy. Neuroscience 211:77-82
16. Freichel C, Neumann M, Ballard T, Müller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, Kahle PJ (2007) Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice. Neurobiol Aging 28:1421-1435
17. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160-164
18. Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou S-S, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA (2013) Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease. PLoS ONE 8:e71634
19. Geser F, Wenning GK, Poewe W, McKeith I (2005) How to diagnose dementia with Lewy bodies: State of the art. Mov Disord 20:S11-S20
20. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T Human α-Synuclein. Neuron 34:521-533
21. Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB (2007) Inhibitory control and spatial working memory in Parkinson's disease. Mov Disord 22:1444-1450
22. Hall H, Jewett M, Landeck N, Nilsson N, Schagerlöf U, Leanza G, Kirik D (2013) Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors. PLoS ONE 8:e64844
23. Halliday G, Holton J, Revesz T, Dickson D (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122:187-204
24. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40:1
25. Hansen C, Björklund T, Petit GH, Lundblad M, Murmu RP, Brundin P, Li J-Y (2013) A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP. Neurobiology of Disease. 56:145-155
26. Hashimoto M, Rockenstein E, Masliah E (2003) Transgenic models of α-synuclein pathology. Ann NY Acad Sci 991:171-188
27. Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan C, Idezuka J, Wakabayashi K, Onodera O, Iwatsubo T, Nishizawa M, Takahashi H, Ishikawa A (2008) Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 65:514-519
28. Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, Parkkinen L, Senior SL, Anwar S, Ryan B, Deltheil T, Kosillo P, Cioroch M, Wagner K, Ansorge O, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Wade-Martins R (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci 110: E4016-E4025
29. Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006) Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. Mov Disord 21:1343-1349
30. Kahle PJ (2008) alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 115:87-95
31. Kahle PJ, Neumann M, Ozmen L, Müller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C (2000) Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain. J Neurosci 20:6365-6373
32. Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL (2009) Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 23(365-370):3. doi:10. 1097/WAD.1090b1013e3181b5065d
33. Kéri S, Nagy H, Myers CE, Benedek G, Shohamy D, Gluck MA (2008) Risk and protective haplotypes of the alpha-synuclein gene associated with Parkinson's disease differentially affect cognitive sequence learning. Genes Brain Behav 7:31-36
34. Kéri S, Moustafa AA, Myers CE, Benedek G, Gluck MA (2010) α-Synuclein gene duplication impairs reward learning. Proc Natl Acad Sci 107:15992-15994
35. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A (2002) Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System. J Neurosci 22:2780-2791
36. Klein RL, King MA, Hamby ME, Meyer EM (2002) Dopaminergic cell loss induced by human A30P a-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13:605-612
37. Kokhan VS, Afanasyeva MA, Van'kin GI (2012) α-Synuclein knockout mice have cognitive impairments. Behav Brain Res 231:226-230
38. Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schröder U, Schöls L, Epplen JT, Riess O, Przuntek H (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56:1355-1362
39. Kuo Y-M, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, Nussbaum RL (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated Î ±-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 19:1633-1650
40. Lam HA, WuN, Cely I, Kelly RL, Hean S, Richter F, Magen I, Cepeda C, Ackerson LC, Walwyn W, Masliah E, Chesselet M-F, Levine MS, Maidment NT (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. J Neurosci Res 89:1091-1102
41. Li B, Arime Y, Hall FS, Uhl GR, Sora I (2010) Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol 628:104-107
42. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, Lee VMY (2011) α-syn suppression reverses synaptic and memory defects in a mouse model of dementia with lewy bodies. J Neurosci 31:10076-10087
43. Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu X-L, Luo J, Long C-X, Ding J, Mateo Y, Sullivan PH, Wu L-G, Goldstein DS, Lovinger D, Cai H (2012) Conditional expression of parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32:9248-9264
44. Lo Bianco C, Ridet JL, Schneider BL, Déglon N, Aebischer P (2002) α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci 99:10813-10818
45. Magen I, Chesselet M-F (2010) Genetic mouse models of Parkinson's disease: the state of the art. Prog Brain Res 184:53-87 (Elsevier, Chapter 4)
46. Magen I, Chesselet M-F (2011) Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinson's Dis 1:217-227
47. Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, David Jentsch J, Chesselet M-F (2012) Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 35:870-882
48. Maingay M, Romero-Ramos M, Carta M, Kirik D (2006) Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol Dis 23:522-532
49. Martin LJ, Semenkow S, Hanaford A, Wong M (2014) The mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice. Neurobiol Aging 35:1132-1152
50. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269
51. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci 98:12245-12250
52. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy Body Disease. PLoS ONE 6:e19338
53. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, DLB co. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863-1872
54. Morra LF, Donovick PJ (2013) Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review. Int J Geriatr Psychiatry n/a-n/a
55. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Müller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Investig 110:1429-1439
56. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Hörsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, Riess O (2008) Neurodegeneration and motor dysfunction in a conditional model of parkinson's disease. J Neurosci 28:2471-2484
57. Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A (2013) Age-dependent effects of A53T alphasynuclein on behavior and dopaminergic function. PLoS ONE 8:e60378
58. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421
59. Pagonabarraga J, Kulisevsky J (2012) Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis 46:590-596
60. Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W, Stolyar P, Vasilyev D, Zaleska M, Hirst WD, Dunlop J (2013) Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson's Disease. PLoS ONE 8:e70274
61. Peña-Oliver Y, Buchman VL, Dalley JW, Robbins TW, Schumann G, Ripley TL, King SL, Stephens DN (2011) Deletion of alpha-synuclein decreases impulsivity in mice. Genes Brain Behav 11:137-146
62. Peterson DA, Elliott C, Song DD, Makeig S, Sejnowski TJ, Poizner H (2009) Probabilistic reversal learning is impaired in Parkinson's disease. Neuroscience 163:1092-1101
63. Pfeiffer HCV, Løkkegaard A, Zoetmulder M, Friberg L, Werdelin L (2013) Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurologica Scandinavica
64. Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E (2010) Alterations in mGluR5 expression and signaling in Lewy Body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS ONE 5:e14020
65. Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hägerström D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C (2009) A Swedish family with de novo α-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 15:627-632
66. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175:35-48
67. Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, Danner S, Schell H, Boden C, Ruegg MA, Kahle PJ, van der Putten H, Shimshek DR (2011) Neuropathology in mice expressing mouse alpha-synuclein. PLoS ONE 6:e24834
68. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL (2004) Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ-synuclein, α-synuclein and double α/γ-synuclein null mutant mice. J Neurochem 89:1126-1136
69. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568-578
70. Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B, Masliah E (2014) Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain
71. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128-1139
72. Rothman SM, Griffioen KJ, Vranis N, Ladenheim B, Cong W-N, Cadet J-L, Haran J, Martin B, Mattson MP (2013) Neuronal Expression of Familial Parkinson's Disease A53T α-Synuclein Causes Early Motor Impairment, Reduced Anxiety and Potential Sleep Disturbances in Mice. J Parkinson's Dis 3:215-229
73. Rothman SM, Griffioen KJ, Fishbein KW, Spencer RG, Makrogiannis S, Cong W-N, Martin B, Mattson MP (2014) Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice. Neurobiol Aging 35:1153-1161
74. Schell H, Hasegawa T, Neumann M, Kahle PJ (2009) Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 160:796-804
75. Schell H, Boden C, Chagas AM, Kahle PJ (2012) Impaired c-fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice. PLoS ONE 7:e50245
76. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ, Wade-Martins R (2008) Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27:947-957
77. Siegmund A, Langnaese K, Wotjak CT (2005) Differences in extinction of conditioned fear in C57BL/6 substrains are unrelated to expression of α-synuclein. Behav Brain Res 157:291-298
78. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) α-synuclein locus triplication causes parkinson's disease. Science 302:841
79. Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E, Zarranz JJ (2011) Initial neuropsychological impairments in patients with the E46 K mutation of the α-synuclein gene (PARK 1). J Neurol Sci 310:86-89
80. Specht CG, Schoepfer R (2004) Deletion of multimerin-1 in α-synuclein-deficient mice. Genomics 83:1176-1178
81. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci 95:6469-6473
82. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 49:313-319
83. Stiedl O, Radulovic J, Lohmann R, Birkenfeld K, Palve M, Kammermeier J, Sananbenesi F, Spiess J (1999) Strain and substrain differences in context-and tone-dependent fear conditioning of inbred mice. Behav Brain Res 104:1-12
84. Szegő ÉM, Gerhardt E, Outeiro TF, Kermer P (2011) Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice. J Neurol Sci 310:90-95
85. Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, Ryan B, Parkkinen L, Deltheil T, Cioroch M, Livieratos A, Oliver PL, Jennings KA, Davies KE, Ansorge O, Bannerman DM, Cragg SJ, Wade-Martins R (2014) Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiol Dis 62:193-207
86. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK (2004) Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur J Neurosci 19:845-854
87. Tofaris GK, Garcia Reitböck P, Humby T, Lambourne SL, O'Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Grazia Spillantini M (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): implications for Lewy Body disorders. J Neurosci 26:3942-3950
88. Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, Kanbe D, Muramatsu S-I, Kobayashi K, Iwatsubo T, Yoshimoto M (2008a) Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiol Aging 29:574-585
89. Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M (2008b) Dopamine receptor agonists reverse behavioral abnormalities of α-synuclein transgenic mouse, a new model of Parkinson's disease. J Neurosci Res 86:640-646
90. Watson GS, Leverenz JB (2010) Profile of cognitive impairment in Parkinson's disease. Brain Pathol 20:640-645
91. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 130:1787-1798
92. Winner B, Lie DC, Rockenstein E, Aigner R, Aigner L, Masliah E, Kuhn HG, Winkler J (2004) Human wild-type α-synuclein impairs neurogenesis. J Neuropathol Exp Neurol 63:1155-1166
93. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91:451-461
94. Yamaguchi K, Cochran E, Murrell J, Polymeropoulos M, Shannon K, Crowther RA, Goedert M, Ghetti B (2005) Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the α-synuclein gene. Acta Neuropathol 110:298-305
95. Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, Inoue H, Takahashi M, Takahashi R (2012) α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res 73:173-177
96. Yang XW, Gong S (2001) An overview on the generation of BAC transgenic mice for neuroscience research. Wiley, Current Protocols in Neuroscience
97. Yang J-H, Han S-J, Ryu JH, Jang I-S, Kim D-H (2009) Ginsenoside Rh2 Ameliorates Scopolamine-Induced Learning Deficit in Mice. Biol Pharm Bull 32:1710-1715
98. Yarnall AJ, Rochester L, Burn DJ (2013) Mild cognitive impairment in Parkinson's disease. Age Ageing 42:567-576
99. Zhou W, Milder JB, Freed CR (2008) Transgenic mice overexpressing tyrosine-to-cysteine mutant human α-synuclein: a progressive nurodegenerative model of diffuse Lewy body disease. J Biol Chem 283:9863-9870